Dyameo has raised $3.3M to back its work on a diagnostic probe that helps clinicians tell whether cells are cancerous during endoscopic exams. The company, a research and development firm in the medical device space, says the tool is designed to give a simple, clear and instant answer to that question, with the aim of catching cancer at an early stage.
Medevice Capital, NACO, Bpifrance, Obratori and Estellior Capital participated in the round.














